Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17159812 | 0.90 | CYP19A1 (0.80) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL3235365 | 0.86 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL15688800 | 0.84 | CYP19A1 (0.71) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL11354103 | 0.82 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL2401045 | 0.82 | CYP19A1 (0.65) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL305950 | 0.81 | CYP19A1 (0.63) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL3318872 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL3319920 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL306232 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL309621 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828361-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160159768-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-06-09 | — | — | US | disclosed |
| EP-1966166-B1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| EP-1966166-B1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| WO-2009095394-A1 | DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-08-06 | — | — | WO | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| EP-1966166-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | Sterix Limited (GB) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068905-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007068905-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159768-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | CYP19A1 132/4885HDAC1 1349/4885HDAC6 792/4885 |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | CYP19A1, CYP21A2, CBR1 | CYP19A1 1/4885HDAC1 1147/4885HDAC6 3152/4885 |
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | CYP19A1 605/4885HDAC1 1848/4885HDAC6 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.